{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.4","upperLimit":"71.1","value":"47.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with response (complete response \\[CR\\] or partial response \\[PR\\]) according to the revised response criteria for malignant lymphoma per Cheson et al. 2007. CR was demonstrated by disappearance of all evidence of disease in the bone marrow, spleen, liver, and lymph nodes. PR was \\>50% decrease in the sum of product diameters (SPD) for ≤6 target masses for lymph nodes and \\>50% decrease in SPD for a single nodule in greatest transverse diameter for spleen and liver, and no size increase in the lymph nodes, spleen, or liver. PD-L1 was assessed by immunohistochemistry (IHC). The percentage of participants with CR and PR as assessed by the investigator is presented for participants with an indeterminate (missing) PD-L1 status.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants from the pooled Cohort 4 NHL sub-cohorts (Cohorts 4A+4B+4C+4D) received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Pooled Cohort 4 Sub-cohorts (Cohorts 4A+4B+4C+4D)"}],"paramType":"NUMBER","populationDescription":"All participants pooled from the Cohort 4 NHL sub-cohorts (Cohorts 4A+4B+4C+4D), who had an indeterminate PD-L1 status, with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation. The analysis was pre-specified to be a pooled analysis of participants grouped by disease cohort (NHL).","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}